Track topics on Twitter Track topics that are important to you
COOLHEAD Pilot Trial Receives First Prize in the Innovative Technology or Device Category
San Diego, CA – June 2, 2015 - BeneChill, Inc. (“BeneChill”, the “Company”) is pleased to announce the recognition of the results of the ‘COOLHEAD’ clinical trial by virtue of its award as the 2015 winner in the Innovation Technology or Device Category for NHS’s annual Bright Ideas in Health Awards. The award recognizes leaders in research and innovation within the NHS in the United Kingdom.
The concept of utilizing nasal cavity cooling for the treatment of acute migraine, as provided by the RhinoChill® System, was developed by Fred Colen, MSEE, CEO of BeneChill. To substantiate the concept, Dr. Jitka Vanderpol from Cumbria Partnership NHS Foundation Trust and the COOLHEAD team developed and conducted the breakthrough COOLHEAD pilot trial at the Penrith Community Hospital, part of the Cumbria Partnership NHS Foundation Trust and published the results.
Out of four finalists, Cumbria Partnership was recognized as the frontrunner for their successful results from the COOLHEAD pilot trial, a study designed to assess the benefits of nasal cavity cooling for the treatment of migraine headaches. The winning team was comprised of: Dr. Jitka Vanderpol, Barbara Bishop, Gillian Webster, Dr. Dave Dagnan, Sandra Glencorse, Dale Healy, Mark Glencorse, Fred Colen and Dr. Manjit Matharu.
The full results from the COOLHEAD trial were published in January, 2015 in the Journal of Headache and Pain (click here).
“I am honored to have been selected as the winner given the many talented peers who applied for the Bright Ideas in Health Awards. Results from the COOLHEAD study illustrate a promising and revolutionary non- pharmacological approach for treating the millions of individuals who suffer from migraine headaches. The COOLHEAD 2 trial will begin recruiting in July of this year to further support evidence of benefit for this exciting new treatment for migraine sufferers around the world” stated Dr. Vanderpol.
“Winning the 12th Bright Ideas in Health Awards is a wonderful validation of our technology and the benefit it can provide for millions of migraine patients needing better treatment options,” remarked Fred Colen, CEO of BeneChill. “The added recognition we are receiving from the healthcare industry and the medical community as a result of the award allows us to showcase BeneChill’s mission of offering a simple, fast and effective solution for treating migraine headaches. Our goal is to expand upon the positive results from the COOLHEAD study and further validate the benefits of nasal cavity cooling for the treatment of migraine headaches.”
About BeneChill, Inc.
BeneChill, Inc. is a medical device company established in 2003 to develop, manufacture, and sell novel rapid cooling products to improve clinical outcomes. BeneChill’s lead product, the RhinoChill® IntraNasal Cooling System (also referred to as the RhinoChill® System, “RhinoChill®”, or the “System”), is designed to deliver targeted, effective and therapeutically beneficial cooling to the nasal cavity and the brain (and to the body via the cooled brain, if so desired). Utilizing a lightweight, portable system design and unique intra-nasal, catheter-based delivery of a quickly evaporating coolant, BeneChill offers a unique opportunity for medical practitioners to protect the brain. BeneChill’s cooling technology is also suitable for applications on conscious patients where a local, short duration cooling of the nasal cavity is of therapeutic benefit, such as for the treatment of acute migraine. BeneChill’s treatment can also be used during Cardiac Arrest, potentially during Traumatic Brain Injury and may be applicable for other surgical procedures. BeneChill is headquartered in San Diego, CA with European locations near Zürich, Switzerland and Düsseldorf, Germany. BeneChill products, while CE marked in Europe for cooling application, are not FDA approved and not available in the US. For further information please visit www.benechill.com.
Certain matters discussed in this release may constitute forward looking statements for the purposes of the Federal Securities Laws, and as such, may involve known and unknown risk. Uncertainties and other factors may cause actual results, performance or activities of BeneChill, Inc. to be materially different from future results of performance or achievements expressed or implied by such forward looking statements. Additional information concerning factors that could cause actual results to be materially different than those in forward looking statements can be found in BeneChill, Inc.’s filings with the Securities and Exchange Commission (SEC). All forward-looking statements are expressly qualified in their entirety by these cautionary statements.BeneChill, Inc. Contact: Fred Colen, Chief Executive Officer email@example.com or Investor Relations Contact: Jennifer K. Zimmons, Ph.D., Investor Relations (917) 214-3514 firstname.lastname@example.org www.benechill.comNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...